Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
European Journal of Cancer2021Vol. 152, pp. 223–232
Citations Over TimeTop 10% of 2021 papers
Joyce O’Shaughnessy, Susana Sousa, Josefina Cruz, Lesley Fallowfield, Päivi Auvinen, Catarina Pulido, Ana Cvetanović, Sharon Wilks, Leonor Ribeiro, Mauricio Burotto, Dirk Klingbiel, Dimitri Messeri, Ari Alexandrou, Peter C. Trask, J. Fredriksson, Z. Machackova, Ljiljana Stamatović, Ernesto Korbenfeld, Jorge Nadal, Hélio Pinczowski, Felipe José Silva Melo Cruz, Gustavo Mota de Sousa, Aline Coelho Gonçalves, Gisah Guilgen, Mauricio Burotto, Antti Jekunen, Päivi Auvinen, Winne Yeo, Eric C. K. Cheng, Hikmat A. Razeq, Fadi Rafic El Karak, Fadi Farhat, Servando C. Huerta, Brizio M. Jaime, Juan P. Feregrino, O. Castillo, Juan Carlos Alcedo, Leonor Ribeiro, Maria Rita Dionísio, Susana Sousa, Catarina Pulido, Salha Bujassoum, Hatoon Bakhraibah, Ana Cvetanović, Ljiljana Stamatović, Álvaro Rodríguez Lescure, Josefina Cruz, Camilla Wendt, Sara Margolin, Helena Granstam Björneklett, Michelina Cairo, Shaker R. Dakhil, Nguyet Le‐Lindqwister, Ling Ma, Kristi McIntyre, Joyce O’Shaughnessy, Svetislava J. Vukelja, Donald Richards, Sharon Wilks, John M. Wallmark
Abstract
Most patients strongly preferred PH FDC SC over P + H IV. PH FDC SC was generally well tolerated, with no new safety signals (even when switching), and offers a quicker alternative to IV infusion.
Related Papers
- → A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action(2020)47 cited
- → Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer(2017)18 cited
- → Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases(2021)9 cited
- → Abstract 3477: Pertuzumab in combination with trastuzumab enhanced the anti-tumor activity in HER2-positive human gastric cancers(2010)3 cited
- → Supplementary Figure 3 from Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer(2023)